These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 23653011)

  • 1. Slowing the Progression of Diabetic Kidney Disease.
    Blazek O; Bakris GL
    Cells; 2023 Jul; 12(15):. PubMed ID: 37566054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential for improved outcomes in the prevention and therapy of diabetic kidney disease through 'stacking' of drugs from different classes.
    Bell DSH; Jerkins T
    Diabetes Obes Metab; 2024 Jun; 26(6):2046-2053. PubMed ID: 38516874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transforming the Care of Patients with Diabetic Kidney Disease.
    Brosius FC; Cherney D; Gee PO; Harris RC; Kliger AS; Tuttle KR; Quaggin SE;
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1590-1600. PubMed ID: 34103350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of diabetic kidney disease. A network meta-analysis.
    Büttner F; Barbosa CV; Lang H; Tian Z; Melk A; Schmidt BMW
    PLoS One; 2023; 18(11):e0293183. PubMed ID: 37917640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyaluronan Inhibition as a Therapeutic Target for Diabetic Kidney Disease: What Is Next?
    Salman L; Martinez L; Faddoul G; Manning C; Ali K; Salman M; Vazquez-Padron R
    Kidney360; 2023 Jun; 4(6):e851-e860. PubMed ID: 37055910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal lactate metabolism is linked to albuminuria and kidney injury in diabetic nephropathy.
    Azushima K; Kovalik JP; Yamaji T; Ching J; Chng TW; Guo J; Liu JJ; Nguyen M; Sakban RB; George SE; Tan PH; Lim SC; Gurley SB; Coffman TM
    Kidney Int; 2023 Dec; 104(6):1135-1149. PubMed ID: 37843477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heterogeneity in protocols and outcomes to study the effect of renin-angiotensin system blockers in inflammatory bowel disease: A systematic review.
    Ferreira-Duarte M; Tonin FS; Duarte-Araújo M; Fernandez-Llimos F; Morato M
    Fundam Clin Pharmacol; 2023 Dec; 37(6):1139-1152. PubMed ID: 37394277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Another evidence that supports the continued use of RAS inhibitors in end-stage kidney diseases.
    Yamazaki O; Shibata S
    Hypertens Res; 2024 Jul; 47(7):1984-1986. PubMed ID: 38658651
    [No Abstract]   [Full Text] [Related]  

  • 9. Medication profiling in women with type 1 diabetes highlights the importance of adequate, guideline-based treatment in low-risk groups.
    Lithovius R; Mutter S; Parente EB; Mäkinen VP; Valo E; Harjutsalo V; Groop PH
    Sci Rep; 2023 Oct; 13(1):17893. PubMed ID: 37857707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Has the time come to step up to "triple therapy" for the treatment of diabetic kidney disease?
    Patoulias D; Popovic DS; Fragakis N; Rizzo M
    Diabetes Res Clin Pract; 2023 Jul; 201():110726. PubMed ID: 37217018
    [No Abstract]   [Full Text] [Related]  

  • 11. Prevention of diabetic kidney disease: negative clinical trials with renin-angiotensin system inhibitors.
    Nelson RG; Tuttle KR
    Am J Kidney Dis; 2010 Mar; 55(3):426-30. PubMed ID: 20005029
    [No Abstract]   [Full Text] [Related]  

  • 12. Diabetic Kidney Disease: A Call to Action: Preface.
    Tuttle KR
    Diabetes Spectr; 2015 Aug; 28(3):158-60. PubMed ID: 26300606
    [No Abstract]   [Full Text] [Related]  

  • 13. Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis. A Meta-analysis of Individual Patient Data from Randomized Trials.
    Roberts JA; Abdul-Aziz MH; Davis JS; Dulhunty JM; Cotta MO; Myburgh J; Bellomo R; Lipman J
    Am J Respir Crit Care Med; 2016 Sep; 194(6):681-91. PubMed ID: 26974879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in diabetic kidney disease.
    Stanton RC
    Curr Diab Rep; 2013 Aug; 13(4):567-73. PubMed ID: 23653011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
    Krairittichai U; Chaisuvannarat V
    J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Present and future in the treatment of diabetic kidney disease.
    Quiroga B; Arroyo D; de Arriba G
    J Diabetes Res; 2015; 2015():801348. PubMed ID: 25945357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.